BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:00 PM
 | 
Mar 11, 2008
 |  BC Extra  |  Company News

Panel backs Schering-Plough's Bridion

FDA's Anesthetic and Life Support Drugs Advisory Committee voted unanimously (10-0) that Schering-Plough (NYSE:SGP) provided enough data from its three pivotal Phase III studies to support the use of Bridion sugammadex for the routine reversal of...

Read the full 171 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >